Fibromyalgia

You have full text access to this OnlineOpen article

Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial†

  1. I. Jon Russell1,‡,§,*,
  2. A. Thomas Perkins2,‡,¶,
  3. Joel E. Michalek1,‡,‖,
  4. Oxybate SXB-26 Fibromyalgia Syndrome Study Group

Article first published online: 30 DEC 2008

DOI: 10.1002/art.24142

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 1, pages 299–309, January 2009

Additional Information

How to Cite

Russell, I. J., Perkins, A. T., Michalek, J. E. and Oxybate SXB-26 Fibromyalgia Syndrome Study Group (2009), Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis & Rheumatism, 60: 299–309. doi: 10.1002/art.24142

Author Information

  1. 1

    The University of Texas Health Science Center at San Antonio

  2. 2

    Raleigh Neurology Associates, Raleigh, North Carolina

  1. ‡

    Drs. Russell, Perkins, and Michalek have received research support from Jazz Pharmaceuticals.

  2. §

    Dr. Russell has received consulting fees and honoraria from Jazz Pharmaceuticals (more than $10,000).

  3. Dr. Perkins has received consulting fees, speaking fees, and honoraria from Jazz Pharmaceuticals (less than $10,000).

  4. ‖

    Dr. Michalek has received consulting fees from Jazz Pharmaceuticals (more than $10,000).

*University Clinical Research Center, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 7868, San Antonio, TX 78229-3900

  1. †

    ClinicalTrials.gov identifier: NCT00087555.

Publication History

  1. Issue published online: 30 DEC 2008
  2. Article first published online: 30 DEC 2008
  3. Manuscript Accepted: 5 SEP 2008
  4. Manuscript Received: 10 AUG 2007

Funded by

  • Orphan Pharmaceuticals, a wholly owned subsidiary of Jazz Pharmaceuticals, Palo Alto, California

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (127K)

REFERENCES

  • 1
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
    Direct Link:
  • 2
    Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28.
    Direct Link:
  • 3
    Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997; 40: 1560–70.
    Direct Link:
  • 4
    Jain AK, Carruthers BM, van de Sande MI, Barron SR, Donaldson CC, Dunne JV, et al. Fibromyalgia syndrome: Canadian clinical working case definition, diagnostic, and treatment protocols: a consensus document. J Musculoskelet Pain 2003; 11: 3–118.
  • 5
    Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995; 22: 151–6.
  • 6
    Wolfe F, Hawley DJ, Cathey MA, Caro X, Russell IJ. Fibrositis: symptom frequency and criteria for diagnosis: an evaluation of 291 rheumatic disease patients and 58 normal individuals. J Rheumatol 1985; 12: 1159–63.
  • 7
    Buskila D, Neumann L. Genetics of fibromyalgia. Curr Pain Headache Rep 2005; 9: 313–5.
  • 8
    Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001; 91: 165–75.
  • 9
    Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002; 46: 1333–43.
    Direct Link:
  • 10
    Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 1998; 315: 377–84.
  • 11
    Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain 2004; 110: 449–60.
  • 12
    Okifuji A, Turk DC, Sherman JJ. Evaluation of the relationship between depression and fibromyalgia syndrome: why aren't all patients depressed? J Rheumatol 2000; 27: 212–9.
  • 13
    Russell IJ, Bieber C. Muscle and fibromyalgia syndrome. In: McMahonSB, KoltzenburgM, editors. Wall and Melzack's textbook of pain. 5th ed. London: Elsevier; 2005.
  • 14
    Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27: 1327–34.
  • 15
    Scharf MB, Hauck M, Stover R, McDannold M, Berkowitz D. Effect of γ-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia: preliminary report. J Rheumatol 1998; 25: 1986–90.
  • 16
    Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003; 30: 1070–4.
  • 17
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-29, DHHS Publication No. (SMA) 07-4256. Rockville (MD): US Department of Health and Human Services; 2007. URL: http://DAWNinfo.samhsa.gov/files/dawn2ked5.htm.
  • 18
    Lai MW, Klein-Schwartz WK, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006; 44: 803–932.
  • 19
    Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728–33.
  • 20
    Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993; 42: 93–9.
  • 21
    Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidem 1988; 41: 313–21.
  • 22
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83.
  • 23
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149–58.
  • 24
    Okifuji A, Turk DC, Sinclair JD, Starz TW, Marcus DA. A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 1997; 24: 377–83.
  • 25
    Moldofsky H, Cesta A, Kwong T, Mously C, Houghton W, Cook H, et al. A randomized, double-blind, placebo-controlled, multicenter study of the beneficial effects of sodium oxybate on pain and sleep in patients with fibromyalgia [abstract]. Sleep 2006; 29 (Suppl): A310.
  • 26
    Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al, and the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264–73.
    Direct Link:
  • 27
    Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al, for the Duloxetine Fibromyalgia Trial Group. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974–84.
    Direct Link:
  • 28
    Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000; 6: 250–7.
  • 29
    Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003; 114: 537–45.
  • 30
    Everson CA. Functional consequences of sustained sleep deprivation in the rat. Behav Brain Res 1995; 69: 43–54.
  • 31
    Lentz MJ, Landis CA, Rothermel J, Shaver JL. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999; 26: 1586–92.
  • 32
    Older SA, Battafarano DF, Danning CL, Ward JA, Grady EP, Derman S, et al. The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects: correlations with insulin-like growth factor I. J Rheumatol 1998; 25: 1180–6.
  • 33
    Smythe HA, Moldofsky H. Two contributions to understanding of the “fibrositis” syndrome. Bull Rheum Dis 1977; 28: 928–31.
  • 34
    Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep 2007; 30: 494–505.
  • 35
    Wedin GP, Hornfeldt CS, Ylitalo LM. The clinical development of γ-hydroxybutyrate (GHB). Curr Drug Saf 2006; 1: 99–106.
  • 36
    Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury: a controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997; 40: 446–52.
    Direct Link:
View Full Article (HTML) Get PDF (127K)